Last reviewed · How we verify
Cyramza (RAMUCIRUMAB)
Cyramza blocks the VEGFR2 receptor, which is involved in cancer cell growth and spread.
Cyramza (ramucirumab) is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist developed by Eli Lilly and Company. It works by blocking the VEGFR2 receptor, which is involved in the growth and spread of cancer cells. Cyramza is approved to treat various types of cancer, including stomach, liver, colon, and lung cancers. The drug is still patented and has a half-life of 14 days. Key safety considerations include hypertension and bleeding risks.
At a glance
| Generic name | RAMUCIRUMAB |
|---|---|
| Sponsor | Eli Lilly |
| Drug class | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] |
| Target | Vascular endothelial growth factor receptor 2 |
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2014 |
| Annual revenue | 900 |
Mechanism of action
Ramucirumab is VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As result, ramucirumab inhibits ligand-stimulated activation of VEGFR2, thereby inhibiting ligand-induced proliferation, and migration of human endothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model.
Approved indications
- Adenocarcinoma of stomach
- Liver cell carcinoma
- Malignant neoplasm of colon and/or rectum
- Malignant tumor of stomach
- Non-small cell lung cancer
Common side effects
- Hypertension
- Diarrhea
- Neutropenia
- Epistaxis
- Stomatitis
- Fatigue/Asthenia
- Infections
- Proteinuria
- Alopecia
- Increased Alanine Aminotransferase
- Increased Aspartate Aminotransferase
- Anemia
Key clinical trials
- A Study in Second Line Metastatic Colorectal Cancer (PHASE3)
- A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (PHASE3)
- A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy (PHASE3)
- A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma (PHASE3)
- Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma (PHASE3)
- A Platform Study in Non-Small Cell Lung Cancer (NSCLC) (PHASE1,PHASE2)
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (PHASE2)
- Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial (PHASE2,PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
| Biologic Exclusivity |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyramza CI brief — competitive landscape report
- Cyramza updates RSS · CI watch RSS
- Eli Lilly portfolio CI